---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044400"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:07:59.915815+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ZyVersa Therapeutics prices $5.0M public offering of common stock and warrants

## Summary
- Offering of 4M shares (or pre-funded warrants in lieu) plus 4M Series A and 4M Series B warrants at combined $1.25 per unit.
- Gross proceeds ~$5.0M; net proceeds for working capital and general corporate purposes.
- Series A warrants $1.25 strike, 5-year term; Series B warrants $1.25 strike, 18-month term, both immediately exercisable.
- Offering closed on December 11, 2023; A.G.P./Alliance Global Partners acted as sole placement agent.

## SEC filing metadata
- accession: 0001493152-23-044400
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223044400/0001493152-23-044400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223044400/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044400
- JSON: https://secwatch.observer/filing/0001493152-23-044400.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044400.txt

## Key facts
- Material Agreements
  ZyVersa Therapeutics, Inc. entered into Securities Purchase Agreement with purchasers identified on the signature pages valued at 400,000 shares of common stock, pre-funded warrants for 3,600,000 shares, Series A common warrants f (effective 2023-12-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: purchasers identified on the signature pages
  - Value: 400,000 shares of common stock, pre-funded warrants for 3,600,000 shares, Series A common warrants f
  - Effective: 2023-12-06
  source text: On December 6, 2023, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement with each purchaser identified on the signature pages thereto (the “Purchase Agreement”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), (i) 400,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) 3,600,000 pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of 3,600,000 shares of Common Stock, (iii) 4,000,000 Series A common warrants (the “Series A Common Warrants”) exercisable for an aggregate of 4,000,000 shares of Common Stock, and (iv) 4,000,000 Series B common warrants (the “Series B Common Warrants,” and together with the Series A Common Warrants, the “Common Warrants”) exercisable for an aggregate of 4,000,000 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223044400/0001493152-23-044400-index.htm
- Material Agreements
  ZyVersa Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee equal to 6.0% of gross proceeds, expense reimbursement up to $80,000, non-accountable expen (effective 2023-12-06).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: cash fee equal to 6.0% of gross proceeds, expense reimbursement up to $80,000, non-accountable expen
  - Effective: 2023-12-06
  source text: On December 6, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which A.G.P. agreed to act as exclusive placement agent for the issuance and sale of the Shares and Warrants.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223044400/0001493152-23-044400-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.